JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Home・Aandelen Lijst・Pacira Pharmaceuticals Inc-DE

Pacira Pharmaceuticals Inc-DE

Gesloten

SectorGezondheidszorg

24.51 -3.16

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

24.2

Max

24.51

Belangrijke statistieken
By Trading Economics
Inkomsten	-3.8M 1.6M
Verkoop	17M 197M
K/W Sectorgemiddelde	155.625 60.328
Winstmarge	0.832
Werknemers	825
EBITDA	-9.8M 25M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+12.2% upside

Dividenden
By Dow Jones
Volgende Winsten	30 apr 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	77M 1.1B
Vorige openingsprijs	27.67
Vorige sluitingsprijs	24.51

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

24.83 / 26.38 Steun & Weerstand

Pacira Pharmaceuticals Inc-DE Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2026, 19:19 UTC

Acquisities, Fusies, Overnames

Intertek Group Rejects EQT's Revised Offer

24 apr 2026, 23:37 UTC

Acquisities, Fusies, Overnames

Scoring the Cook Era -- Barrons.com

24 apr 2026, 20:51 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Financial Services Roundup: Market Talk

24 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

24 apr 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 20:09 UTC

Winsten

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 apr 2026, 19:48 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 apr 2026, 19:25 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 19:25 UTC

Acquisities, Fusies, Overnames

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 apr 2026, 19:22 UTC

Winsten

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 apr 2026, 19:06 UTC

Winsten

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 apr 2026, 19:05 UTC

Marktinformatie

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 apr 2026, 18:30 UTC

Acquisities, Fusies, Overnames

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 apr 2026, 18:28 UTC

Acquisities, Fusies, Overnames

Intertek Rejects Revised EQT Offer

24 apr 2026, 18:12 UTC

Marktinformatie

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 apr 2026, 18:06 UTC

Marktinformatie

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 apr 2026, 17:42 UTC

Winsten

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 apr 2026, 17:28 UTC

Winsten

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 apr 2026, 17:28 UTC

Marktinformatie

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 apr 2026, 17:12 UTC

Marktinformatie

Global Equities Roundup: Market Talk

24 apr 2026, 17:11 UTC

Marktinformatie

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 apr 2026, 17:09 UTC

Marktinformatie

Winsten

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 apr 2026, 17:09 UTC

Acquisities, Fusies, Overnames

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr 2026, 17:06 UTC

Winsten

Acquisities, Fusies, Overnames

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 apr 2026, 16:51 UTC

Winsten

Acquisities, Fusies, Overnames

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 apr 2026, 16:20 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

24 apr 2026, 16:20 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Financial Services Roundup: Market Talk

24 apr 2026, 16:20 UTC

Marktinformatie

Winsten

Auto & Transport Roundup: Market Talk

24 apr 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Pacira Pharmaceuticals Inc-DE Prognose

Koersdoel

By TipRanks

12.2% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 27.5 USD 12.2%

Hoogste 38 USD

Laagste 22 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pacira Pharmaceuticals Inc-DE - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Pacira Pharmaceuticals Inc-DE - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

24.83 / 26.38Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Bullish events outweigh bearish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.